In a nutshell The aim of this study was to investigate how safe and effective fast-acting insulin aspart (faster aspart) is compared to insulin aspart (NovoRapid, NovoLog) when used in a continuous insulin pump in type 1 diabetes (T1D). The main finding was that faster aspart is a safe and effective option in a continuous insulin pump for these...
Read MoreHow safe and effective is fast-acting insulin aspart in a continuous insulin infusion in type 1 diabetes?
